U.S. Partners to Strengthen Pharmaceutical Supply Chain Resilience

• •The U.S. is assessing vulnerabilities in its pharmaceutical supply chain.
• •Key starting materials (KSMs) are critical for drug manufacturing.
• •The initiative aims to reduce reliance on foreign sources and improve domestic production.

The U.S. Department of Health and Human Services, along with the Departments of Commerce and War, is assessing vulnerabilities in the pharmaceutical supply chain, focusing on key starting materials (KSMs) essential for drug manufacturing. This initiative aims to enhance domestic production capabilities and address reliance on foreign sources. ASPR Principal Deputy Assistant Secretary Sean Kaufman emphasized the importance of understanding the origins of these materials to prepare for public health emergencies. The assessment will include a survey of U.S. manufacturers and suppliers to gather data on production capacities and supply chain disruptions. Findings will inform funding strategies to bolster the pharmaceutical supply chain's resilience. This effort follows a previous survey on active pharmaceutical ingredients (APIs) conducted earlier in 2026, which highlighted significant domestic production challenges.